Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes

Linda J.C. Van Waalwijk Van Doorn, Juan D. Gispert, H. Bea Kuiperij, Jurgen A.H.R. Claassen, Andrea Arighi, Inês Baldeiras, Kaj Blennow, Marco Bozzali, Miguel Castelo-Branco, Enrica Cavedo, Derya D. Emek-Savaş, Erden Eren, Paolo Eusebi, Lucia Farotti, Chiara Fenoglio, Juan Fortea Ormaechea, Yvonne Freund-Levi, Giovanni B. Frisoni, Daniela Galimberti, Sermin GencViviana Greco, Harald Hampel, Sanna-Kaisa Herukka, Yawu Liu, Albert Lladó, Alberto Lleó, Flavio M. Nobili, Kader K. Oguz, Lucilla Parnetti, João Pereira, Agnese Picco, Maria Pikkarainen, Catarina Resende De Oliveira, Esen Saka, Nicola Salvadori, Raquel Sanchez-Valle, Isabel Santana, Elio Scarpini, Philip Scheltens, Hilkka Soininen, Roberto Tarducci, Charlotte Teunissen, Magda Tsolaki, Andrea Urbani, Eduard Vilaplana, Pieter Jelle Visser, Asa K. Wallin, Görsev Yener, José L. Molinuevo, Olga Meulenbroek, Marcel M. Verbeek

Risultato della ricerca: Contributo in rivistaArticolo in rivista

7 Citazioni (Scopus)

Abstract

Cerebrospinal fluid (CSF) biomarkers may support the diagnosis of Alzheimer's disease (AD). We studied if the diagnostic power of AD CSF biomarker concentrations, i.e., Aβ42, total tau (t-tau), and phosphorylated tau (p-tau), is affected by differences in lateral ventricular volume (VV), using CSF biomarker data and magnetic resonance imaging (MRI) scans of 730 subjects, from 13 European Memory Clinics. We developed a Matlab-algorithm for standardized automated segmentation analysis of T1 weighted MRI scans in SPM8 for determining VV, and computed its ratio with total intracranial volume (TIV) as proxy for total CSF volume. The diagnostic power of CSF biomarkers (and their combination), either corrected for VV/TIV ratio or not, was determined by ROC analysis. CSF Aβ42 levels inversely correlated to VV/TIV in the whole study population (Aβ42: r=-0.28; p<0.0001). For CSF t-tau and p-tau, this association only reached statistical significance in the combined MCI and AD group (t-tau: r=-0.15; p-tau: r=-0.13; both p<0.01). Correction for differences in VV/TIV improved the differentiation of AD versus controls based on CSF Aβ42 alone (AUC: 0.75 versus 0.81) or in combination with t-tau (AUC: 0.81 versus 0.91). In conclusion, differences in VV may be an important confounder in interpreting CSF Aβ42 levels.
Lingua originaleEnglish
pagine (da-a)543-555
Numero di pagine13
RivistaJournal of Alzheimer's Disease
Volume56
DOI
Stato di pubblicazionePubblicato - 2017

Keywords

  • Aged
  • Algorithms
  • Alzheimer Disease
  • Alzheimer's disease
  • Amyloid beta-Peptides
  • Area Under Curve
  • Atrophy
  • Biomarkers
  • Cerebral Ventricles
  • Cognitive Dysfunction
  • Female
  • Hippocampus
  • Humans
  • Image Interpretation, Computer-Assisted
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Organ Size
  • Pattern Recognition, Automated
  • Peptide Fragments
  • ROC Curve
  • amyloid biomarkers
  • cerebrospinal fluid
  • lateral ventricles
  • tau Proteins
  • tau protein

Fingerprint

Entra nei temi di ricerca di 'Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes'. Insieme formano una fingerprint unica.

Cita questo